Seer and Korea University Present Preliminary Data at ASMS 2026 Demonstrating Potential of AI-Driven Plasma Proteomics for Multi-Cancer Screening
Rhea-AI Summary
Seer (Nasdaq: SEER) and Korea University reported preliminary ASMS 2026 data showing AI-driven analysis of deep plasma proteomics for potential multi-cancer screening.
The collaboration analyzed over 5,500 plasma samples across ten major cancer types, averaging 14,000 protein groups per sample, and targets more than 20,000 clinical samples overall.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – SEER
On the day this news was published, SEER gained 1.15%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous AI Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 26 | AI proteomics showcase | Positive | +1.1% | Planned ASMS 2026 presentations on AI-driven multi-cancer screening and tools. |
| Jun 01 | AI cancer study launch | Positive | +11.5% | Announcement of 20,000-sample AI-driven cancer diagnostics study with Korea University. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
SEER’s prior AI-focused announcements have typically led to positive share price reactions.
Historical Comparison
In the past AI-tagged releases, SEER’s shares moved an average of 6.27%, with prior Korea University AI collaborations drawing clearly positive reactions. This update extends that same multi-cancer screening program.
AI-tagged history shows a clear progression: announcing the 20,000-sample AI cancer study, then showcasing capabilities at ASMS, and now presenting preliminary multi-cancer screening data from thousands of plasma samples.
Regulatory & Risk Context
Reported short interest appears relatively low, suggesting limited short-squeeze fuel but also a smaller base of bearish positioning that could dampen volatility from covering activity.
Key Terms
plasma proteomics medical
proteome medical
mass spectrometry technical
self-supervised AI models technical
id-free ai framework technical
orbitrap astral mass spectrometer technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Findings from more than 5,500 plasma samples demonstrate the feasibility of combining deep plasma proteomics generated by the Proteograph Product Suite with ID-Free AI approaches across ten major cancer types
REDWOOD CITY, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leader in deep, unbiased proteomics, today announced preliminary data presented at the 2026 American Society for Mass Spectrometry (ASMS) Annual Conference demonstrating the potential of the Proteograph® Product Suite to enable AI-driven approaches for multi-cancer screening. The findings were presented by Sang-Won Lee, Ph.D., Professor at Korea University and Chief Executive Officer of TargetX, and Jaewoo Kang, Ph.D., Professor at Korea University and Chief Executive Officer of AIGEN Sciences, during the Seer Breakfast Symposium on June 1 in San Diego.
“By incorporating the Proteograph platform into our plasma proteomics workflow, we are able to profile the plasma proteome at remarkable depth and scale across thousands of patient samples with the reproducibility required for large-scale clinical research,” said Dr. Lee. “Equally important, the quality and consistency of the data enable us to explore new computational approaches that extend beyond conventional identification-based analyses. By combining deep proteomic datasets generated using the Proteograph and Orbitrap Astral mass spectrometer combined with our ID-Free AI framework, we can learn directly from a substantially larger portion of the underlying data and uncover biological patterns that may otherwise remain inaccessible.”
“The Proteograph platform significantly expands the breadth and depth of proteomic information captured from plasma samples,” said Dr. Kang. “Applying self-supervised AI models directly to these rich datasets allows us to extract biological signal beyond what traditional workflows can utilize. This creates an opportunity to investigate whether previously untapped information can contribute to future multi-cancer screening approaches.”
“The convergence of AI and large-scale biology will require datasets of unprecedented depth, quality, and scale,” said Omid Farokhzad, Chair and Chief Executive Officer of Seer. “The work presented by Drs. Lee and Kang exemplifies the type of transformative science the Proteograph platform was designed to enable. Their early findings provide an exciting glimpse into how deep proteomic datasets, analyzed with advanced AI methods, may help unlock new approaches to disease detection and biological discovery. We are proud to support this pioneering research and the scientific community's efforts to push the boundaries of what is possible.”
At ASMS, Drs. Lee and Kang presented results from an ongoing collaboration between Seer and Korea University focused on generating one of the largest deep, unbiased plasma proteomics datasets assembled to date. The analysis included more than 5,500 plasma samples spanning ten major cancer types and healthy controls.
The researchers reported deep and highly reproducible plasma proteome coverage at population scale, averaging more than 14,000 protein groups per sample, while enabling the construction of a comprehensive cohort-derived proteomic reference resource. They also described an emerging ID-Free AI framework designed to leverage the substantial portion of mass spectrometry data that remains uncharacterized by conventional identification-based workflows. Together, these efforts establish a foundation for evaluating whether additional biological information contained within complex proteomic datasets can improve future multi-cancer screening strategies.
The findings represent an early milestone in an ongoing collaboration between Seer and Korea University that is expected to analyze more than 20,000 clinical plasma samples across ten of Korea's highest-incidence cancer types.
About Seer, Inc.
Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics, delivering insights with scale, speed, precision, and reproducibility previously unattainable by other proteomic methods. Seer's Proteograph Product Suite integrates proprietary engineered nanoparticles, automation instrumentation, optimized consumables, and advanced analytical software. Seer's products are for research use only and are not intended for diagnostic procedures. For more information, visit www.seer.bio.
Forward-Looking Statements
This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are based on Seer’s beliefs and assumptions and on information available to Seer as of the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties, and other factors that may cause Seer’s actual results, performance, or achievements to be materially different from those expressed or implied by the forward-looking statements. These statements include, but are not limited to, statements regarding the potential of the Proteograph platform to enable AI-driven multi-cancer screening and statements regarding Seer’s plans, strategies, expectations, strategic opportunities, research and development initiatives, and prospects. These risks are described more fully in Seer’s filings with the Securities and Exchange Commission and other documents that Seer subsequently files with the Securities and Exchange Commission from time to time. Except to the extent required by law, Seer undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Media Contact:
Patrick Schmidt
pr@seer.bio
Investor Contact:
Marissa Bych or Caylene Parrish
investor@seer.bio
